NTX-301

A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients With MDS and AML

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
20 patients (estimated)
Sponsors
University of Alabama at Birmingham
Tags
DNMT1 Inhibitor
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1569
NCT Identifier
NCT04167917

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.